Acute Migraine Clinical Trial
Official title:
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
This is a randomized, double-blind, multi-center, parallel group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo. Subjects who have consented and meet the entry criteria will be randomized to one of four blinded treatment groups. There will be a screening period of up to 1 week, followed by a run-in period to record migraine activity. The run-in period is to determine eligibility for randomization, and is planned to be 4 weeks in duration but may be extended up to an additional 4 weeks to accommodate scheduling. Qualified subjects will randomize to the double-blind treatment period at Day 0 and will have up to 8 weeks to confirm and treat a qualifying migraine. Using the eDiary to confirm they are experiencing a qualified migraine, subjects will self-administer the patch or patches and continue to respond to questions in the eDiary for 48 hours post treatment administration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04153409 -
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
|
Phase 2 | |
| Completed |
NCT02279082 -
DFN-02 Open Label Safety Study in Patients With Acute Migraine
|
Phase 3 | |
| Completed |
NCT04574362 -
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
|
Phase 3 | |
| Completed |
NCT01973205 -
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine
|
Phase 3 | |
| Terminated |
NCT04089761 -
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
|
N/A | |
| Completed |
NCT03631550 -
The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
|
N/A | |
| Completed |
NCT01267864 -
Valproate Versus Ketorolac Versus Metoclopramide
|
Phase 4 | |
| Completed |
NCT05371652 -
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
|
Phase 3 | |
| Completed |
NCT04218162 -
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
|
Phase 3 | |
| Completed |
NCT01730326 -
Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack
|
Phase 4 | |
| Completed |
NCT04408794 -
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
|
Phase 2/Phase 3 | |
| Completed |
NCT00894556 -
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
|
Phase 3 | |
| Terminated |
NCT02185703 -
Chordate System S020 Acute Migraine Clinical Investigation
|
N/A | |
| Terminated |
NCT01680029 -
PBASE-system Acute Migraine Clinical Investigation
|
N/A | |
| Completed |
NCT01358279 -
Transcranial Direct Current Stimulation for Migraine Attack
|
N/A | |
| Not yet recruiting |
NCT01228552 -
The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine
|
Phase 3 | |
| Completed |
NCT02684409 -
Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine
|
Phase 1 | |
| Completed |
NCT02439320 -
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
|
Phase 3 | |
| Terminated |
NCT01112553 -
Treximet Migraine Brain Imaging Research Study
|
N/A | |
| Completed |
NCT01276977 -
Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
|
N/A |